A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
Status:
Active, not recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
The main aims of this study are to learn how lanadelumab moves through a child's body and if
the children have any medical problems from lanadelumab. Other aims are to learn if
prophylactic treatment with lanadelumab reduces the number and severity of HAE attacks in
children, how lanadelumab affects the child's body, and if the children develop antibodies to
lanadelumab.
The study doctors will treat acute HAE attacks according to their standard practice.
Participants will receive lanadelumab for up to 52 weeks. When they start treatment,
participants will visit their clinic every week for the first 4 weeks. Then, they will visit
their clinic every 4 weeks during treatment.